长期的多巴胺激动剂治疗未能恢复不安腿综合征中改变的中央感官处理:来自当前感知值测量的证据
Hung Youl Seok1, Yong Won Cho1
1Department of Neurology, Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
Sleep medicine
|November 15, 2023
概括
对不安腿综合征 (RLS) 的长期多巴胺激动剂治疗改善了症状,但并没有改变当前感知值 (CPT) 测试所测量的中央感官处理.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
背景情况:
- 不安腿综合征 (RLS) 与改变的中央感官处理有关.
- 短期多巴胺激动剂治疗对RLS感官处理的影响已知,但长期影响仍未得到充分研究.
研究的目的:
- 研究多巴胺激动剂治疗对RLS患者中央感官处理的长期影响.
- 为了评估长期多巴胺激动剂治疗后当前感知值 (CPT) 的变化.
主要方法:
- 一项涉及24名RLS患者的研究,他们接受多巴胺激动剂治疗至少2个月.
- 当前感知值 (CPT) 测试在治疗前和治疗后进行.
- 根据症状改善,患者被分为响应者或不响应者.
主要成果:
- 多巴胺激动剂治疗显著改善了RLS临床参数 (IRLS评分,VAS,RLS-QoL).
- 在治疗后的刺激频率之间没有观察到CPT值的显著变化.
- 在响应者和非响应者之间没有发现CPT变化的显著差异.
结论:
- 长期的多巴胺激动剂治疗有效地管理RLS症状.
- 这种治疗不能逆转RLS患者中改变的中央感官处理.
- RLS病理生理学可能是多因素的,超出了多巴胺功能障碍.
相关概念视频
Restless Leg Syndrome and Night Terrors
183
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
183
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
348
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
348
Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K


